Comment from Aditya Sanjeev

Summary: Aditya Sanjeev, an independent researcher in clinical AI fairness, supports the pilot program by providing specific technical recommendations to improve its safety and oversight. He argues that the FDA should mandate disaggregated subgroup performance reporting, worst-case performance metrics, and multi-seed evaluation protocols to prevent "minority collapse" in AI models.